Protein expression in the nucleus accumbens of rats exposed to developmental vitamin D deficiency

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  McGrath, John ^a,b   Iwazaki, Takeshi ^c   Eyles, Darryl ^a,b   Burne, Thomas ^a,b   Cui, Xiaoying ^a,b   Ko, Pauline ^a,b   Matsumoto, Izuru ^c,d  

^a QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Asahiyama Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALBINDIN; DYNAMIN; HIPPOCALCIN; NERVE PROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIRTH; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENOMICS; MALE; MASS SPECTROMETRY; MATING; MITOCHONDRION; NONHUMAN; NUCLEUS ACCUMBENS; OUTCOME ASSESSMENT; PROGENY; PROTEIN EXPRESSION; PROTEOMICS; RAT; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VITAMIN D DEFICIENCY; ANIMAL; METABOLISM;

ANIMALIA; RATTUS;

ANIMALS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; MALE; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VITAMIN D DEFICIENCY;

EID: 48649104440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002383     Document Type: Article

References (49)

1. McGrath J (1999) Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 40: 173-177.
2. Davies G, Welham J, Chant DC, Torrey EF, McGrath J (2003) Season of birth effect and latitude: a systematic review and meta-analysis of Northern Hemisphere studies. Schizophr Bull 29: 587-593.
3. Saha S, Chant DC, Welham JL, McGrath JJ (2006) The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiatrica Scandinavica 114: 36-39.
4. Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67: 373-378.
5. Eyles D, BrownJ, Mackay-Sim A, McGrath J, Feron F (2003) Vitamin D3 and brain development. Neuroscience 118: 611-653.
6. Ko P, Burkert R, McGrath J, Eyles D (2004) Maternal vitamin D(3) deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res Dev Brain Res 153: 61-68.
7. Cui Y, McGrath JJ, Burne TH, Mackay-Sim A, Eyles DW (2007) Maternal vitamin D depletion alters neurogenesis in the developing rat brain. Int J Dev Neurosci 25: 227-232.
8. Feron F, Burne TH, Brown J, Smith E, McGrath JJ, et al. (2005) Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res Bull 65: 141-148.
9. Burne TH, Becker A, Brown J, Eyles DW, Mackay-Sim A, et al. (2004) Transient prenatal Vitamin D deficiency is associated with hyperlocomotion in adult rats. Behav Brain Res 154: 549-555.
10. Kesby JP, Burne TH, McGrath JJ, Eyles DW (2006) Developmental vitamin D deficiency alters NK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia. Biol Psychiatry 60: 591-596.
11. Becker A, Eyles DW, McGrath JJ, Grecksch G (2005) Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behav Brain Res 161: 306-312.
12. O'Loan J, Eyles DW, Kesby J, Ko P, McGrath JJ, et al. (2007) Vitamin D deficiency during various stages of pregnancy in the rat; its impact on development and behaviour in adult offspring. Psychoneuroendocrinology 32: 227-234.
13. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
14. Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, et al. (2008) Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33: 368-377.
15. Joseph MH, Darla K, Young AM (2003) The interpretation of the measurement of nucleus accumbens dopamine by in vivo dialysis: the kick, the craving or the cognition? Neurosci Biobehav Rev 27: 527-541.
16. Lauer M, Senitz D, Beckmann H (2001) Increased volume of the nucleus accumbens in schizophrenia. J Neural Transm 108: 645-660.
17. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic, neurons and control of goal-directed behaviors. Trends Neurosci 30: 220-227.
18. Almeras L, Eyles D, Benech P, Laffite D, Villard C, et al. (2007) Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 7: 769-780.
19. Eyles D, Almeras L, Benech P, Patatian A, Mackay-Sim A, et al. (2007) Developmental vitamin D deFiciency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol 103: 538-545.
20. Thompson TL, Moss RL (1997) Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett 229: 145-148.
21. Zhou W, Cunningham KA, Thomas ML (2002) Estrogen regulation of gene expression in the brain: a possible mechanism altering the response to psychostimulants in female rats. Brain Res Mol Brain Res 100: 75-83.
22. Paxinos G, Watson C (2004) The Rat Brain in Stereotaxic Coordinates - the New Coronal Set. New York: Academic Press.
23. Alexander-Kaufman A, G J, Sheerly D, Harper C, Matsumoto I (2005) Differential protein expression in the prefrontaol white matter of human alcoholics: a proteomics study.
24. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254.
25. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate, a practical and powerful approach to multiple testing. J Roy Stat Soc, Series B 57: 289-300.
26. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
27. Eyles DW, McGrath JJ, Reynolds GP (2002) Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 57: 27-34.
28. Lewis DA, Hashimoto T (2007) Deciphering the disease process of schizophrenia: the contribution of cortical gaba neurons. Int Rev Neurobiol 78: 109-131.
29. Christakos S, Dhawan P, Peng X, Obukhov AG, Nowycky MC, et al. (2007) New insights into the function and regulation of vitamin D target proteins J Steroid Biochem Mol Biol 103: 405-410.
30. McCann JC, Ames BN (2008) Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 22: 982-1001.
31. Royle SJ, Lagnado, L (2003) Endocytosis at the synaptic terminal. J Physiol 553: 315-355.
32. Paspalas CD, Rakic P, Goldman-Rakic PS (2006) Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci 24: 1395-1403.
33. Scorrano L (2007) Multiple functions of mitochondria-shaping proteins. Novartis Foundation Symposium 287: 47-55; discussion 55-49.
34. Chen G, Racay P, Bichet S, Celio MR, Eggli P, et al. (2006) Deficiency in parvalbumin, but not in calbindin D-28k upregulates mitochondrial volume and decreases smooth endoplasmic reticulum surface selectively in a peripheral, subplasmalemmal region in the soma of Purkinje cells. Neuroscience 142: 97-105.
35. Prensa I, Richard S, Parent A (2003) Chemical anatomy of the human ventral striatum and adjacent basal forebrain structures. J Comp Neurol 460: 345-367.
36. Meredith GE, Bado BA, Andrezjewski ME, Kelley AE (2008) The structural basis for mapping behavior onto the ventral striatum and its subdivisions. Brain Structure and Function.
37. Saric T, Graef CI, Goldberg AL (2004) Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279: 46723-46732.
38. Ferraro L, Tomasini MC, Fuxe K, Agnati LF, Mazza R, et al. (2007) Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides. Brain Res Rev 55: 144-154.
39. Caceda R, Kinkead B, Nemcroff CB (2006) Neurotensin: role in psychiatric and neurological diseases. Peptides 27: 2385-2404.
40. Boules M, Shaw A, Fredrickson P, Richelson E (2007) Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21: 13-23.
41. Oliveira V, Garrido PA, Rodrigues CC, Colquhoun A, Castro LM, et al. (2005) Calcium modulates endopeptidase 24.15 (EC 3.4.24.15) membrane association, secondary structure and substrate specificity. Febs J 272: 2978-2992.
42. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, et al. (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics; 6: 3414-3425.
43. Escarrilla M (2007) Variation in the malic enzyme 2 gene: implications for the pharmacogenomics of psychotic disorders. Pharmacogenomics 8: 691-695.
44. Lee BD, Walss-Bass C, Thompson PM, Dassori A, Montero PA, et al. (2007) Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res 150: 1-11.
45. Middleton FA, Mimics K, Pierri JN, Lewis DA, Levitt P (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729.
46. Vawter MP, Shannon Weickert C, Ferran E, Matsumoto M, Overman K, et al. (2004) Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res 29: 1245-1255.
47. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, et al. (2004) Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67: 41-52.
48. Kyosseva SV (2004) Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 997-1006.
49. Andrade EC, Krueger DD, Nairn AC (2007) Recent advances in neuroproteomics. Current Opinion in Molecular Therapeutics 9: 270-281.